['diabetes mellitus, type 2']
['ly2944876', 'exenatide extended-release', 'placebo']

        Inclusion Criteria:

          -  Men or women with diabetes mellitus Type 2

          -  Have screening HbA1c ≥7.0% and ≤10.5% either on diet and exercise alone or on a stable
             dose of metformin (≥1000 mg/day) for 3 months prior to screening

          -  Have body mass index (BMI) ≥23 and ≤45 kilograms per meter squared at screening

        Exclusion Criteria:

          -  Women of child bearing potential

          -  Participants who have used thiazolidinediones within 3 months prior to screening, or
             any other drugs for treatment of hyperglycemia (except metformin) within the prior 2
             months

          -  Participants who have used insulin for diabetic control for more than 6 consecutive
             days within the prior year

          -  Participants with impaired renal function (serum creatinine >124 micromole per liter
             (µmol/L) [1.4 milligrams per deciliter (mg/dL)] in women, >133 µmol/L [1.5 mg/dL] in
             men)
      